Mucoaricodil (Ambroxol Hydrochloride)

Mucoaricodil is a mucolytic that acts on the respiratory tract to thin and clear mucus.

• Cough with thick mucus: improves expectoration and reduces cough intensity.
• Bronchitis: facilitates clearance of sputum and eases breathing discomfort.
• Respiratory tract infections: assists in mucus removal, supporting recovery and symptom relief.

• Ambroxol Hydrochloride stimulates serous cells in the respiratory mucosa, increasing the production of thin, watery secretions while decreasing mucus viscosity. The resulting reduction in mucus thickness enhances ciliary activity and promotes expectoration, helping to clear the airways during infections or inflammatory conditions.

Adverse reactions may occur with ambroxol use and are reported with varying frequency.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Taste disturbance: a temporary bitter or metallic taste.
• Abdominal discomfort: mild cramps or pain.
• Diarrhea: loose stools occurring shortly after dosing.
• Headache: mild, transient headache.
• Skin rash: mild erythema or itching.

Serious or Rare Side Effects

• Allergic reactions: hives, swelling, or difficulty breathing.
• Stevens‑Johnson syndrome: severe skin blistering and detachment.
• Anaphylaxis: rapid onset of systemic allergic response.
• Eosinophilia: elevated eosinophil count in blood.
• Liver enzyme elevation: abnormal hepatic function tests.
• Severe skin reactions: toxic epidermal necrolysis or drug rash with eosinophilia and systemic symptoms.

When prescribing or dispensing Mucoaricodil, consider the following safety measures.

• Renal function assessment: adjust use in patients with severe renal impairment.
• Hepatic monitoring: use cautiously in liver disease and monitor liver enzymes.
• Allergy screening: avoid in individuals with known hypersensitivity to ambroxol or related compounds.
• Pregnancy consideration: evaluate risk‑benefit ratio before use in pregnant or breastfeeding women.
• Concomitant medication review: watch for interactions that may affect bleeding or mucosal integrity.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Ambroxol may influence the activity of other medicines; clinicians should review patient medication lists.

Major Interactions (Avoid)

• Codeine‑containing antitussives: may mask cough and reduce therapeutic monitoring.
• Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): can increase ambroxol plasma levels.
• Anticoagulants (e.g., warfarin): may enhance bleeding risk, requiring close INR monitoring.

Moderate Interactions (Monitor Closely)

• Bronchodilators (e.g., salbutamol): additive bronchodilatory effect may cause tachycardia.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase gastrointestinal irritation.
• Alcohol: can exacerbate stomach upset and dizziness.